Shawn Tomasello bought stock once, on Jan 21, 2026

Shawn Tomasello is an independent Director at Cabaletta Bio, Inc. (CABA), appointed in July 2023, where she serves on the Compensation Committee and Science & Technology Committee.( With over 35 years in the life sciences industry, she holds a B.S. in Marketing from the University of Cincinnati and an M.B.A. from Murray State University, and was age 66 as of April 2025.(

Tomasello's career highlights include serving as Chief Commercial Officer (CCO) at Kite Pharma (2015–2018), leading the global launch of Yescarta, the first approved CAR-T therapy for non-Hodgkin lymphoma, through Gilead's acquisition; CCO at Pharmacyclics (2014–2015), managing Imbruvica prior to AbbVie's buyout; President of Americas Hematology & Oncology at Celgene with five product launches; and National Director of Hematology for Rituxan at Genentech over ~14 years.( She has served on multiple public and private biotech boards, including current roles at 4D Molecular Therapeutics (FDMT) (since 2020) and Centrexion Therapeutics (since 2017), and a brief CEO stint at CoRegen, Inc. (Jan–Apr 2025).( Recently, as a CABA Director, she purchased 22,725 shares on January 21, 2026, at $2.21 per share.(

Written by Perplexity from public sources.